Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825-34 - Shariat, Shahrokh F; Laukhtina, Ekaterina (European urology, 2024)
Keywords: Muscles; Gemcitabine; svaly; lidé; Nivolumab; Neoadjuvant Therapy; gemcitabin; Urinary Bladder Neoplasms; nivolumab; cisplatina; protokoly protinádorové kombinované chemoterapie; Humans; Cisplatin; Antineoplastic Combined Chemotherapy Protocols; nádory močového měchýře; neoadjuvantní terapie